利拉鲁肽联合二甲双胍对肥胖型2型糖尿病患者胰岛β细胞功能的影响被引量：8

下载PDF

导出

摘要选取2016年5月到2018年5月肥胖型2型糖尿病患者96例,随机平分成对照组给予二甲双胍,观察组接受利拉鲁肽联合二甲双胍治疗。结果观察组治疗后三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、血清总胆固醇(TC)、稳态模型胰岛素抵抗指数(HOMA-IR)低于对照组,胰岛β细胞分泌指数(HOMA-β)高于对照组,(P <0. 05)。结论利拉鲁肽与二甲双胍联合治疗肥胖型2型糖尿病患者可有效改善胰岛β细胞功能,降低血脂水平。

作者王俊孙守萍

机构地区河南省信阳市第三人民医院

出处《实用糖尿病杂志》 2019年第5期56-57,共2页 Journal of Practical Diabetology

关键词肥胖型2型糖尿病利拉鲁肽二甲双胍胰岛Β细胞功能血脂

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献4

1王琳,刘启胜,朱四民,王会芳.利拉鲁肽对Ⅱ型糖尿病伴肥胖患者胰岛β细胞功能和微炎症状态的影响[J].西部医学,2017,29(7):966-969. 被引量：18
2菅小红,申晶,徐建宾,刘洋,陈一梅.利拉鲁肽注射液治疗超重及肥胖的2型糖尿病伴微量白蛋白尿患者的临床研究[J].中国临床药理学杂志,2018,34(24):2803-2806. 被引量：18
3贺美芳,冯希云,梁文芳,王芳,赵静雅,兰丽珍.利拉鲁肽联合二甲双胍治疗肥胖2型糖尿病患者临床疗效观察[J].中国药物与临床,2016,16(4):579-581. 被引量：43
4韩秀平,孙涛,汪丽丽,贺钰梅,张梅,李转霞,李林娟,张永莉.利拉鲁肽与二甲双胍对初发2型糖尿病伴肥胖患者体质情况、代谢和微炎症状态的影响[J].海南医学院学报,2016,22(16):1792-1795. 被引量：34

二级参考文献54

1胡仁明,李洪超.胰高血糖素样多肽-1类药治疗2型糖尿病的复合终点评价[J].中华糖尿病杂志,2010,2(4). 被引量：16
2Li CJ,Li J,Zhang QM,et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin doseincrease in Chinese subjects with poorly controlled type 2 diabetes and abdomi-nal obesity[J].Cardiovasc Diabetol,2012,11:142.
3Hoist JJ.The physiology of glucagon-like peptidel[J].Physiol Rev,2007,87(4):1409-1439.
4Drueker DJ,Nauck MA.The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].Lancet,2006,368(9548):1696-1705.
5Nauck MA,Meier JJ,Creutzfeldt W.Incretins and their analogues a8 new antidiabetic drugs[J].Drug News Perspect,2003,16(7):413-422.
6Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomized,52-week,phaseⅢ,double-blind,paralleltreatment trial[J].Lancet,2009,373(56):473-481.
7Marre M,Shaw J,Brandle M,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J].Diabetic Med,2009,26(8):268-278.
8Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,65(3):84-90.
9Malo MS.A high level of intestinal alkaline phosphatase is protective against type 2 diabetes mellitusirrespective of obesity[J].EBioMedicine,2015,2(12):2016-2023.
10Ghane Basiri M,Sotoudeh G,Djalali M,et al.Association of major dietary patterns with general and abdominal obesity in iranian patients withtype 2 diabetes mellitus[J].Int J Vitam Nutr Res,2015,85(3-4):145-155.